Gram negative infections in cystic fibrosis: a review of preventative and treatment options

References

• Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519–2531.
   PubMed Web of Science ®Google Scholar
• Bell SC, De Boeck K, Amaral MD.New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.Pharmacol Ther. 2015;19-34.
   Google Scholar
• CF-TRUST. Cystic fibrosis trust - reporting and resources London: CF trust; 2018 [cited 2020 Jan 03]. Available from: https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources
   Google Scholar
• Burgel PRR, Bellis G, Olesen HV, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015;46:133–141.
   PubMed Web of Science ®Google Scholar
• DA S, DK M, MJ W. Origins of cystic fibrosis lung disease. N Engl J Med. 2015;372:363.
   PubMedGoogle Scholar
• Dhooghe B, Noël S, Huaux F, et al. Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem. 2014;47:539–546.
   PubMed Web of Science ®Google Scholar
• Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261:5–16.
   PubMed Web of Science ®Google Scholar
• Parkins MD, Floto RA. Review: emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J Cyst Fibros. 2015;14:293–304.
   PubMed Web of Science ®Google Scholar
• Hisert KB, Heltshe SL, Pope C, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med. 2017;195:1617–1628.
   PubMed Web of Science ®Google Scholar
• Ramsay KA, Sandhu H, Geake JB, et al. The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. J Cyst Fibros. 2017;16:70–77.
   PubMed Web of Science ®Google Scholar
• Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. J Am Med Assoc. 2005;293:581–588.
   PubMed Web of Science ®Google Scholar
• LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010;23:299–323.
   PubMed Web of Science ®Google Scholar
• Breuer O, Schultz A, Turkovic L, et al. The changing prevalence of lower airway infections in young children with cystic fibrosis. Am J Respir Crit Care Med. 2019;200:590–599.
   PubMed Web of Science ®Google Scholar
• Zlosnik JE, Speert DP. The role of mucoidy in virulence of bacteria from the Burkholderia cepacia complex: a systematic proteomic and transcriptomic analysis. J Infect Dis. 2010;202:770–781.
   PubMed Web of Science ®Google Scholar
• Regan KH, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019;4:1465-1858.
   Web of Science ®Google Scholar
• Gilligan PH, Downey DG, Elborn JS, et al. “Pathogen eradication” and “emerging pathogens”: difficult definitions in cystic fibrosis. J Clin Microbiol. 2018;56:e00193–18.
   PubMed Web of Science ®Google Scholar
• Huang YJ, Charlson ES, Collman RG, et al. The role of the lung microbiome in health and disease. A national heart, lung, and blood institute workshop report. Am J Respir Crit Care Med. 2013;187:1382–1387.
   PubMed Web of Science ®Google Scholar
• Conrad D, Haynes M, Salamon P, et al. Cystic fibrosis therapy: A community ecology perspective. Am J Respir Cell Mol Biol. 2013;48:150–156.
   PubMed Web of Science ®Google Scholar
• Sherrard LJ, Tunney MM, Elborn JS. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet. 2014;384:703–713.
   PubMed Web of Science ®Google Scholar
• Berdah L, Taytard J, Leyronnas S, et al. Stenotrophomonas maltophilia: a marker of lung disease severity. Pediatr Pulmonol. 2018;53:426–430.
   PubMed Web of Science ®Google Scholar
• Flume PA. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. J Cyst Fibros. 2016;15:139–140.
   PubMed Web of Science ®Google Scholar
• Sherrard LJ, Bell SC, Tunney MM. The role of anaerobic bacteria in the cystic fibrosis airway. Curr Opin Pulm Med. 2016;22:637–643.
   PubMed Web of Science ®Google Scholar
• Caverly LJ, Zhao J, LiPuma JJ. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection. Pediatr Pulmonol. 2015;50:S31–8.
   PubMed Web of Science ®Google Scholar
• Mahboubi MA, Carmody LA, Foster BK, et al. Culture-based and culture-independent bacteriologic analysis of cystic fibrosis respiratory specimens. J Clin Microbiol. 2016;54:613–619.
   PubMed Web of Science ®Google Scholar
• Burns JL, Rolain J-M. Culture-based diagnostic microbiology in cystic fibrosis: can we simplify the complexity? J Cyst Fibros. 2014;13:1–9.
   PubMed Web of Science ®Google Scholar
• Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–178.
   PubMed Web of Science ®Google Scholar
• Tunney MM, Klem ER, Fodor AA, et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax. 2011;66:579–584.
   PubMed Web of Science ®Google Scholar
• Prior AR, Gunaratnam C, Humphreys H. Ralstonia species – do these bacteria matter in cystic fibrosis? Paediatr Respir Rev. 2017;23:78–83.
   PubMed Web of Science ®Google Scholar
• Caskey S, Moore J, McCaughan J, et al. Belfast Agar–a simple laboratory medium to separate Pseudomonas aeruginosa from pan-resistant Burkholderia cenocepacia isolated from the sputum of patients with cystic fibrosis (CF). Br J Biomed Sci. 2018;75:101–103.
   PubMed Web of Science ®Google Scholar
• Gillow C, Shaw A, Moore JE, et al. Antibiotic resistance and identification of uncommon gram-negative bacteria isolated from sputum of adult patients with cystic fibrosis. Br J Biomed Sci. 2006;63:22–25.
   PubMed Web of Science ®Google Scholar
• Coburn B, Wang PW, Diaz Caballero J, et al. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015;5:10241.
   PubMed Web of Science ®Google Scholar
• Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Nat Acad Sci; 2012 109:5809–5814.
   PubMed Web of Science ®Google Scholar
• Carmody LA, Zhao J, Kalikin LM, et al. The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation. Microbiome. 2015;3:12.
   PubMed Web of Science ®Google Scholar
• Willner D, Haynes MR, Furlan M, et al. Spatial distribution of microbial communities in the cystic fibrosis lung. Isme J. 2012;6:471–474.
   PubMed Web of Science ®Google Scholar
• Pattison SH, Rogers GB, Crockard M, et al. Molecular detection of CF lung pathogens: current status and future potential. J Cyst Fibros. 2013;12:194–205.
   PubMed Web of Science ®Google Scholar
• Flight WG, Smith A, Paisey C, et al. Rapid detection of emerging pathogens and loss of microbial diversity associated with severe lung disease in cystic fibrosis. J Clin Microbiol. 2015;53:2022–2029.
   PubMed Web of Science ®Google Scholar
• Taylor RFH, Costa LD, Kaufmann ME, et al. Pseudomonas cepacia pulmonary infection in adults with cystic fibrosis: is nosocomial acquisition occurring? J Hosp Infect. 1992;21:199–204.
   PubMed Web of Science ®Google Scholar
• Fung SK, Dick H, Devlin H, et al. Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis. Can J Infect Dis. 1998;9:177–182.
   PubMedGoogle Scholar
• Pegues DA, Carson LA, Tablan OC, et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. J Pediatr. 1994;124:694–702.
   PubMed Web of Science ®Google Scholar
• Tümmler B, Koopmann U, Grothues D, et al. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991;29:1265–1267.
   PubMed Web of Science ®Google Scholar
• Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35:s1–s67.
   PubMed Web of Science ®Google Scholar
• Wood ME, Stockwell RE, Johnson GR, et al. Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei. Thorax. 2019;74:87–90.
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Emerson J, McNamara S, et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros. 2012;11:446–453.
   PubMed Web of Science ®Google Scholar
• Ramsay KA, Butler CA, Paynter S, et al. Factors influencing acquisition of burkholderia cepacia complex organisms in patients with cystic fibrosis. J Clin Microbiol. 2013;51:3975–3980.
   PubMed Web of Science ®Google Scholar
• Steinkamp G, Ullrich G. Different opinions of physicians on the importance of measures to prevent acquisition of Pseudomonas aeruginosa from the environment. J Cyst Fibros. 2003;2:199–205.
   PubMedGoogle Scholar
• Collaco JM, McGready J, Green DM, et al. Effect of temperature on cystic fibrosis lung disease and infections: A replicated cohort study. PLoS ONE. 2011;6:e27784.
   PubMed Web of Science ®Google Scholar
• Psoter KJ, De Roos AJ, Wakefield J, et al. Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Clin Microbiol Infect. 2013;19:E483–9.
   PubMedGoogle Scholar
• Stanojevic S, Ratjen F, Stephens D, et al. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros. 2013;12:575–583.
   PubMed Web of Science ®Google Scholar
• Amin R, Waters V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst Rev. 2016;7:1465-1858.
   Web of Science ®Google Scholar
• Dubois CL, Boudreau V, Tremblay F, et al. Association between glucose intolerance and bacterial colonisation in an adult population with cystic fibrosis, emergence of Stenotrophomonas maltophilia. J Cyst Fibros. 2017;16:418–424.
   PubMed Web of Science ®Google Scholar
• Recio R, Brañas P, Martínez MT, et al. Effect of respiratory Achromobacter spp. infection on pulmonary function in patients with cystic fibrosis. J Med Microbiol. 2018;67:952–956.
   PubMed Web of Science ®Google Scholar
• Ullrich G, Wiedau S, Schulz W, et al. Parental knowledge and behaviour to prevent environmental P. aeruginosa acquisition in their children with CF. J Cyst Fibros. 2008;7:231–237.
   PubMed Web of Science ®Google Scholar
• Granchelli AM, Adler FR, Keogh RH, et al. Microbial interactions in the cystic fibrosis airway. J Clin Microbiol. 2018;56:e00354–18.
   PubMed Web of Science ®Google Scholar
• Smyth AR, Rosenfeld M. Prophylactic anti‐staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2017;4:1465-1858.
   Web of Science ®Google Scholar
• Ronchetti K, Tame J-D, Paisey C, et al. The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med. 2018;6:461–471.
   PubMed Web of Science ®Google Scholar
• Lillquist YP, Cho E, Davidson AGF. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs 2009. J Cystic Fibrosis. 2011;10:175–180.
   PubMed Web of Science ®Google Scholar
• Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2017;4:1465-1858.
   Web of Science ®Google Scholar
• Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010;65:286–291.
   PubMed Web of Science ®Google Scholar
• Tiddens HAWM, De Boeck K, Clancy JP, et al. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: the ALPINE study. J Cyst Fibros. 2015;14:111–119.
   PubMed Web of Science ®Google Scholar
• AR HL S, Brown M, Jones A, et al. Intravenous vs oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): A randomised controlled trial. Paediatric Pulmonol. 2019;54:S302.
   Web of Science ®Google Scholar
• Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect. 2010;16:821–830.
   PubMed Web of Science ®Google Scholar
• Horsley A, Webb K, Bright-Thomas R, et al. Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy? Front Cell Infect Microbiol. 2011;1:18.
   PubMed Web of Science ®Google Scholar
• Ledson MJ, Gallagher MJ, Robinson M, et al. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. J Aerosol Med. 2002;15:51–57.
   PubMedGoogle Scholar
• Garcia BA, Carden JL, Goodwin DL, et al. Implementation of a successful eradication protocol for Burkholderia cepacia complex in cystic fibrosis patients. BMC Pulm Med. 2018;18:35.
   PubMed Web of Science ®Google Scholar
• Somayaji R, Stanojevic S, Tullis DE, et al. Clinical outcomes associated with achromobacter species infection in patients with cystic fibrosis. Ann Am Thorac Soc. 2017;14:1412–1418.
   PubMed Web of Science ®Google Scholar
• Edwards BD, Greysson-Wong J, Somayaji R, et al. Prevalence and outcomes of achromobacter species infections in adults with cystic fibrosis: A North American cohort study. J Clin Microbiol. 2017;55:2074–2085.
   PubMed Web of Science ®Google Scholar
• Wang M, Ridderberg W, Hansen CR, et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros. 2013;12:638–643.
   PubMed Web of Science ®Google Scholar
• Lee TWR, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2:29–34.
   PubMedGoogle Scholar
• Waters VJ, Ratjen FA. Is there a role for antimicrobial stewardship in cystic fibrosis? Ann Am Thorac Soc. 2014;11:1116–1119.
   PubMedGoogle Scholar
• Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA. 2010;303:1707–1715.
   PubMed Web of Science ®Google Scholar
• Samson C, Tamalet A, Thien HV, et al. Long-term effects of azithromycin in patients with cystic fibrosis. Respir Med. 2016;117:1–6.
   PubMed Web of Science ®Google Scholar
• Tullis DE, Burns JL, Retsch-Bogart GZ, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial. J Cyst Fibros. 2014;13:296–305.
   PubMed Web of Science ®Google Scholar
• Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11:57–80.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Vataire A-L-L, Fukushima A, et al. Comparison of inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa lung infection in patients with cystic fibrosis: systematic literature review and network meta-analysis. Clin Ther. 2016;38:2204–2226.
   PubMed Web of Science ®Google Scholar
• Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J Cyst Fibros. 2013;12:130–140.
   PubMed Web of Science ®Google Scholar
• Oermann CM, Retsch‐Bogart GZ, Quittner AL, et al. An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 2010;45:1121–1134.
   PubMed Web of Science ®Google Scholar
• Tappenden P, Harnan S, Uttley L, et al. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model. Health Technol Assess. 2013;17(56):v-xvii, 1-181.
   Web of Science ®Google Scholar
• Dorkin HL, Staab D, Operschall E, et al. Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis. BMJ Open Respir Res. 2015;2:e000100.
   PubMed Web of Science ®Google Scholar
• Elborn JS. Ciprofloxacin dry powder inhaler in cystic fibrosis. BMJ Open Respir Res. 2016;3:e000125.
   PubMed Web of Science ®Google Scholar
• Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017;195:814–823.
   PubMed Web of Science ®Google Scholar
• Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68:818–825.
   PubMed Web of Science ®Google Scholar
• Heltshe SL, Goss CH. Optimising treatment of CF pulmonary exacerbation: a tough nut to crack. Thorax. 2016;71:101–102.
   PubMed Web of Science ®Google Scholar
• Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10:258–264.
   PubMed Web of Science ®Google Scholar
• Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011;183:635–640.
   PubMed Web of Science ®Google Scholar
• VanDevanter DR, Pasta DJ, Konstan MW. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2015;14:763–769.
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RCL, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182:627–632.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Ramotar K, Ferris W, et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2004;169:811–815.
   PubMed Web of Science ®Google Scholar
• Wark PAB, Tooze M, Cheese L, et al. Viral infections trigger exacerbations of cystic fibrosis in adults and children. Eur Respir J. 2012;40:510–512.
   PubMed Web of Science ®Google Scholar
• Miró-Cañís S, Capilla-Rubio S, Marzo-Checa L, et al. Multiplex PCR reveals that viruses are more frequent than bacteria in children with cystic fibrosis. J Clin Virol. 2017;86:1–4.
   PubMed Web of Science ®Google Scholar
• Stressmann FA, Rogers GB, Marsh P, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros. 2011;10:357–365.
   PubMed Web of Science ®Google Scholar
• Excellence NIfHaC. Cystic fibrosis: diagnosis and management. NICE guideline [NG78]. 2017.
   Google Scholar
• Waters V, Stanojevic S, Klingel M, et al. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2015;14:770–776.
   PubMed Web of Science ®Google Scholar
• Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med. 2010;182:1137–1143.
   PubMed Web of Science ®Google Scholar
• Hendry J, Elborn JSS, Nixon L, et al. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. J Cyst Fibros. 2012;14:460–469.
   Google Scholar
• Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE. 2012;7:e45001.
   PubMed Web of Science ®Google Scholar
• CF-MATTERS. First Results;2019 [2020 Jan 03]. Available from: https://www.cfmatters.eu/the-project/first-results/
   Google Scholar
• Kraynack NC, Gothard MD, Falletta LM, et al. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across us CF care centers. Pediatr Pulmonol. 2011;46:870–881.
   PubMed Web of Science ®Google Scholar
• Gramegna A, Millar BC, Blasi F, et al. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting gram-negative bacteria in adults with cystic fibrosis. J Glob Antimicrob Resist. 2018;14:224–227.
   PubMed Web of Science ®Google Scholar
• Starner TD, Zhang N, Kim G, et al. Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med. 2006;174:213–220.
   PubMed Web of Science ®Google Scholar
• Campos J, Román F, Georgiou M, et al. Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis. 1996;174:1345–1347.
   PubMed Web of Science ®Google Scholar
• Waters V, Atenafu EG, Salazar JG, et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros. 2012;11:8–13.
   PubMed Web of Science ®Google Scholar
• Wildman MJ, Hoo ZH. Moving cystic fibrosis care from rescue to prevention by embedding adherence measurement in routine care. Paediatr Respir Rev. 2014;15:16–18.
   PubMed Web of Science ®Google Scholar
• Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros. 2018;17(3):S53.
   Google Scholar
• Frost FJ, Nazareth DS, Charman SC, et al. Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens: a cohort study using national registry data. Ann Am Thorac Soc. 2019; 201902–122OC.
   Web of Science ®Google Scholar
• Singh SB, McLearn‐Montz AJ, Milavetz F, et al. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. Pediatr Pulmonol. 2019;54:1200-1208.
   Web of Science ®Google Scholar
• Sagel SD. The challenges of developing effective anti-inflammatory agents in cystic fibrosis. J Cyst Fibros. 2015;14:164–166.
   PubMed Web of Science ®Google Scholar
• Chmiel JF, Konstan MW, Accurso FJ, et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: implications for clinical trials in cystic fibrosis. J Cyst Fibros. 2015;14:720–726.
   PubMed Web of Science ®Google Scholar
• Davies JC. The future of CFTR modulating therapies for cystic fibrosis. Curr Opin Pulm Med. 2015;21:579–584.
   PubMed Web of Science ®Google Scholar
• Reznikov LR, Abou Alaiwa MH, Dohrn CL, et al. Antibacterial properties of the CFTR potentiator ivacaftor. J Cyst Fibros. 2014;13:515–519.
   PubMed Web of Science ®Google Scholar
• Payne JE, Dubois AV, Ingram RJ, et al. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens. Int J Antimicrob Agents. 2017;50:427–435.
   PubMed Web of Science ®Google Scholar
• Schneider EK, Azad MAK, Han ML, et al. An “unlikely” pair: the antimicrobial synergy of polymyxin b in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI. ACS Infect Dis. 2016;2:478–488.
   PubMed Web of Science ®Google Scholar
• Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with g551d-cftr treated with ivacaftor. Clinl Infect Dis. 2015;60:703–712.
   PubMed Web of Science ®Google Scholar
• Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in g551d-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190:175–184.
   PubMed Web of Science ®Google Scholar
• Konstan MW, McKone EF, Moss RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2016;5:107–118.
   PubMed Web of Science ®Google Scholar
• McColley SA, Konstan MW, Ramsey BW, et al. Lumacaftor/ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV 1. J Cyst Fibros. 2019;18:94–101.
   PubMed Web of Science ®Google Scholar
• Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for phe508del. N Engl J Med. 2017;377:2013–2023.
   PubMed Web of Science ®Google Scholar
• Keating D, Marigowda G, Burr L, et al. VX-445–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two phe508del alleles. N Engl J Med. 2018;379:1612–1620.
   PubMed Web of Science ®Google Scholar
• Davies JC, Moskowitz SM, Brown C, et al. VX-445–tezacaftor–ivacaftor in patients with cystic fibrosis and one or two phe508del alleles. N Engl J Med. 2018;379:1599–1611.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Horsley A, MacGregor G, et al. Phase I studies of acebilustat: biomarker response and safety in patients with cystic fibrosis. Clin Transl Sci. 2017;10:28–34.
   PubMed Web of Science ®Google Scholar